openPR Logo
Press release

Antifibrinolytic Drugs Market New Business Opportunities is Expected to reach $19,333 million by 2026

04-01-2020 12:19 PM CET | Health & Medicine

Press release from: Allied Market Research

Antifibrinolytic Drugs Market

Antifibrinolytic Drugs Market

The global antifibrinolytic drugs market size is expected to reach $19,333 million by 2026, registering a CAGR of 4.5% from 2019 to 2026, in terms of value.

Antifibrinolytic is the class of drugs that is widely used to inhibit fibrinolysis by stopping activation of the proenzyme plasminogen to plasmin. This intrusion is crucial for averting clot degradation in areas rich in the fibrinolysis prone areas such as oral cavity, nasal cavity, and female reproductive tract. Approved antifibrinolytic drugs include Epsilon aminocaproic acid, Tranexamic acid, Amicar, aminocaproic acid, aprotinin, and Cyklokapron. In addition, these drugs find their application in surgeries such as cardiovascular surgeries, neurosurgeries, and dental surgeries. Furthermore, antifibrinolytic drugs are used by women to control heavy menstrual flow.

Download Free Report Sample @ https://www.alliedmarketresearch.com/request-sample/6279

Considerable increase in road accidents, rise in medical surgeries including cardiac, and dental, and surge in prevalence of angioedema are the major factors that drive the antifibrinolytic drugs market growth. Antifibrinolytic drugs play a vital role in averting clot lysis and thereby, blood loss.

The antifibrinolytic drugs market is segmented on the basis of indication, end-users, and region. On the basis of indication, it is classified into gynecology, hereditary angiedema, fibrinolytic response testing, surgeries, and others. By end user, it is divided into hospitals & clinics, ambulatory surgical centers, and healthcare specialty process. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

By type, the gynaecology segment accounted for majority of the market share in 2018 and is expected to exhibit a prominent growth rate in the near future, owing to the increased adoption of these drugs to prevent menorrhagia i.e. heavy menstrual flow. Further, these drugs are manufactured to reduce bleeding by inhibiting endometrial clot-dissolving enzymes in the uterine lining. Tranexamic acid (TXA) is the most widely used drug for controlling menorrhagia.

By end user, the hospitals & clinics segment dominated the antifibrinolytic drugs market in 2018 and is anticipated to maintain its dominance during the forecast period. This is attributed to the increased usage of these drugs in hospitals as most of the surgeries such as cardiovascular and neurosurgeries are performed in hospitals.

Inquire before buying @ https://www.alliedmarketresearch.com/purchase-enquiry/6279

North America accounted for most of the Antifibrinolytics Drug Market share in 2018, and is anticipated to continue this trend during the forecast period. This is attributed to the increased adoption of these drugs by women to control heavy menstrual flow. Moreover, significant surge in surgeries in this region propels the market growth. However, the Asia-Pacific region is anticipated to grow at the fastest rate due to surge in road accidents and increased usage of these drugs by women to control heavy menstrual flow.

The Major Key Players Are:

Acic Fine Chems, Xanodyne Pharmaceuticals, Aurobindo Pharma Ltd., Akorn, Amerigen Pharms Ltd, Mylan, Pfizer (GenMed), Sanofi, Zydus Cadila and Takeda are provided in this report.

Key Findings of the Study:

o By indication, the gynecology segment accounted for the highest Antifibrinolytics Drug Market share of 28% in 2018, and is anticipated to grow at the fastest rate during the forecast period.
o By region, North America was the major shareholder and accounted for the highest share of 42% in 2018.
o Asia-Pacific is expected to grow at a CAGR of 6.1% during the forecast period.
o By end user, the hospital & clinics segment dominated the market in 2018 and is anticipated to maintain its dominance during the forecast period.

Access Full Report @ https://www.alliedmarketresearch.com/antifibrinolytic-drugs-market

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

About Us:

Allied Market Research (AMR) is a full-service market research and business -consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Antifibrinolytic Drugs Market New Business Opportunities is Expected to reach $19,333 million by 2026 here

News-ID: 1994437 • Views: 427

More Releases from Allied Market Research

Cell Therapy Market Size to Exceed USD 48.11 Billion by 2027
The cell therapy market was estimated at $7.75 Billion in 2019, and is expected to hit $48.11 billion by 2027, registering a CAGR of 25.6% from 2020 to 2027. The Cell Therapy Market has gained immense popularity globally due to the advent of techniques like stem cell therapy, CAR-T cell therapy, and cord blood cell therapy. Each of the therapies has gained traction owing to their extensive application in cancer
Home Care Monitoring and Diagnostics Market to See Extensive Worldwide Growth
Global Home Care Monitoring and Diagnostics Market report it provides a vital recent industry data which covers in general market situation along with future scenario for industry around the Globe. It also consists of major data along with forecasts of a global market along with clear presentation of diagrams (charts and tables). According to a new report published by Allied Market Research, titled, “Home Care Monitoring and Diagnostics Market by Product
Neuropeptide Y Receptor Market to Obtain Awesome Hike in Revenues
Global Neuropeptide Y Receptor Market report it provides a vital recent industry data which covers in general market situation along with future scenario for industry around the Globe. It also consists of major data along with forecasts of a global market along with clear presentation of diagrams (charts and tables). According to a new report published by Allied Market Research, titled, “Neuropeptide Y Receptor Market by Product (Food Grade and Pharmaceutical
Infused Dried Fruits Market Size is Set for Rapid Growth and Industry Trend by 2 …
Infused dried fruits are infused with fruit sugar solution through osmotic pressure and dried at 60°C temperature. These fruits have low calories and have low added sugar. The infused dried fruit companies have to follow standards like HACCP, BRC, IFS, and ISO22000. The infused dried fruits are vegan products that have high vitamin C, and are gluten and GMO-free. These products are also suitable for diabetics because they do not

All 5 Releases


More Releases for Antifibrinolytic

Antifibrinolytic Drugs Market Size & Share by Application, Type and Region - Glo …
MarketResearchReports.Biz announces addition of new report "Antifibrinolytic Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025" to its database. The main objective of this report is to define, describe, and forecast the global “Antifibrinolytic Drugs” market on the basis of types of applications, major sectors, deployment models, organization size, and regions. The report contains an analysis of the major factors influencing the growth of the
Antifibrinolytic Drugs Market: Report Scope and Market Segmentation 2017 - 2025
Hemostatic agents prevent the blood loss and have the different site of action in complex coagulation and fibrinolysis pathways. Antifibrinolytic drugs inhibit the activation of plasminogen to plasmin preventing the lysis of fibrin and maintaining the clot stability. These Antifibrinolytic drugs prevent excessive bleeding. Tranexamic acid is used when the risk of hemorrhage is high because of increased fibrinolysis. Aprotinin, a proteolytic enzyme inhibitor which acts on plasmin and kallikrein.
Antifibrinolytic Drugs Market Will Generate New Growth Opportunities By 2025
Tissue damage leads to rupture of vessels which triggers hemostatic mechanism. Hemostasis is a physiological mechanism of the body, wherein vessels contract, platelet plugs are formed, and coagulation starts, resulting in a stable fibrin network. Fibrinolysis is activated during this mechanism. Fibrinolysis is a physiological process in which blood clots are dissolved and tissue damage is remolded. Antifibrinolytic drugs are used to induce clot formation and to prevent blood loss
Antifibrinolytic Drugs Market Set to Record Exponential Growth by 2025
Hemostatic agents prevent the blood loss and have the different site of action in complex coagulation and fibrinolysis pathways. Antifibrinolytic drugs inhibit the activation of plasminogen to plasmin preventing the lysis of fibrin and maintaining the clot stability. These Antifibrinolytic drugs prevent excessive bleeding. Tranexamic acid is used when the risk of hemorrhage is high because of increased fibrinolysis. Aprotinin, a proteolytic enzyme inhibitor which acts on plasmin and kallikrein.
Antifibrinolytic Drugs Market Opportunities and Forecasts, 2017 – 2025
Hemostatic agents prevent the blood loss and have the different site of action in complex coagulation and fibrinolysis pathways. Antifibrinolytic drugs inhibit the activation of plasminogen to plasmin preventing the lysis of fibrin and maintaining the clot stability. These Antifibrinolytic drugs prevent excessive bleeding. Tranexamic acid is used when the risk of hemorrhage is high because of increased fibrinolysis. Aprotinin, a proteolytic enzyme inhibitor which acts on plasmin and kallikrein.
Antifibrinolytic Drugs Market Foreseen to Grow Exponentially Over 2017 - 2025 : …
Hemostatic agents prevent the blood loss and have the different site of action in complex coagulation and fibrinolysis pathways. Antifibrinolytic drugs inhibit the activation of plasminogen to plasmin preventing the lysis of fibrin and maintaining the clot stability. These Antifibrinolytic drugs prevent excessive bleeding. Tranexamic acid is used when the risk of hemorrhage is high because of increased fibrinolysis. Aprotinin, a proteolytic enzyme inhibitor which acts on plasmin and kallikrein.